Successful non-T cell-depleted HLA haplo-identical three-loci mismatched hematopoietic stem cell transplantation from mother to son based on the feto-maternal microchimerism in chronic myelogenous leukemia

Bone Marrow Transplant. 2002 Dec;30(11):793-6. doi: 10.1038/sj.bmt.1703736.

Abstract

A 17-year-old male with chronic myelogenous leukemia in blast crisis received a non-T cell-depleted (TCD) HLA haplo-identical three-loci mismatched hematopoietic stem cell transplant (HSCT) from his mother. Long-term feto-maternal microchimerism was detected by nested polymerase chain reaction with sequence-specific primer typing. The post-transplantation prophylaxis against graft-versus-host disease (GVHD) was tacrolimus with minidose methotrexate. Sustained engraftment was obtained. Acute GVHD (grade 2) developed, but improved rapidly. Bone marrow aspiration on day 120 showed complete remission. Non-TCD HLA haplo-identical HSCT based on feto-maternal microchimerism might be feasible and has important implications in the selection of alternative family donors in HSCT.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Female
  • Graft vs Host Disease / drug therapy
  • Graft vs Host Disease / prevention & control
  • Haplotypes
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Histocompatibility Testing
  • Histocompatibility*
  • Humans
  • Immune Tolerance*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Methotrexate / therapeutic use
  • Nuclear Family
  • Tacrolimus / therapeutic use
  • Transplantation Chimera*
  • Treatment Outcome

Substances

  • Tacrolimus
  • Methotrexate